Protein kinase signaling networks in cancer

Current Opinion in Genetics and Development

Volumn 21, Issue 1, 2011, Pages 4-11

  Brognard, John ^b   Hunter, Tony ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; ANAPLASTIC LYMPHOMA KINASE; B RAF KINASE; B RAF KINASE INHIBITOR; EPHRIN A3; EPHRIN B2; EPHRIN B3; EPHRIN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN KINASE LKB1; PROTEIN TYROSINE KINASE INHIBITOR; RAF PROTEIN; RAPAMYCIN; TRANSCRIPTION FACTOR FOXO; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNINDEXED DRUG;

BREAST CANCER; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; COLON CANCER; DRUG PROTEIN BINDING; DRUG RESPONSE; GENE MUTATION; HUMAN; INTRACELLULAR SIGNALING; LUNG NON SMALL CELL CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

GENETIC TESTING; HUMANS; MUTATION; NEOPLASMS; PROTEIN KINASES; SIGNAL TRANSDUCTION;

EID: 79551632876     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gde.2010.10.012     Document Type: Review

References (74)

1. Hunter T. Treatment for chronic myelogenous leukemia: the long road to imatinib. J Clin Invest 2007, 117:2036-2043.
2. Flaherty K.T., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., O'Dwyer P.J., Lee R.J., Grippo J.F., Nolop K., et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363:809-819.
3. Bollag G., Hirth P., Tsai J., Zhang J., Ibrahim P.N., Cho H., Spevak W., Zhang C., Zhang Y., Habets G., et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010, 467:596-599.
4. Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., Davies H., Teague J., Butler A., Stevens C., et al. Patterns of somatic mutation in human cancer genomes. Nature 2007, 446:153-158.
5. Grueneberg D.A., Degot S., Pearlberg J., Li W., Davies J.E., Baldwin A., Endege W., Doench J., Sawyer J., Hu Y., et al. Kinase requirements in human cells. I. Comparing kinase requirements across various cell types. Proc Natl Acad Sci U S A 2008, 105:16472-16477.
6. Grueneberg D.A., Li W., Davies J.E., Sawyer J., Pearlberg J., Harlow E. Kinase requirements in human cells. IV. Differential kinase requirements in cervical and renal human tumor cell lines. Proc Natl Acad Sci U S A 2008, 105:16490-16495.
7. Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Kamiyama H., Jimeno A., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806.
8. Manning B.D. Challenges and opportunities in defining the essential cancer kinome. Sci Signal 2009, 2:15.
9. Wood L.D., Parsons D.W., Jones S., Lin J., Sjoblom T., Leary R.J., Shen D., Boca S.M., Barber T., Ptak J., et al. The genomic landscapes of human breast and colorectal cancers. Science 2007, 318:1108-1113.
10. Baldwin A., Grueneberg D.A., Hellner K., Sawyer J., Grace M., Li W., Harlow E., Munger K. Kinase requirements in human cells. V. Synthetic lethal interactions between p53 and the protein kinases SGK2 and PAK3. Proc Natl Acad Sci U S A 2010, 107:12463-12468.
11. Baldwin A., Li W., Grace M., Pearlberg J., Harlow E., Munger K., Grueneberg D.A. Kinase requirements in human cells. II. Genetic interaction screens identify kinase requirements following HPV16 E7 expression in cancer cells. Proc Natl Acad Sci U S A 2008, 105:16478-16483.
12. Bommi-Reddy A., Almeciga I., Sawyer J., Geisen C., Li W., Harlow E., Kaelin W.G., Grueneberg D.A. Kinase requirements in human cells. III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen. Proc Natl Acad Sci U S A 2008, 105:16484-16489.
13. Bardelli A., Parsons D.W., Silliman N., Ptak J., Szabo S., Saha S., Markowitz S., Willson J.K., Parmigiani G., Kinzler K.W., et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 2003, 300:949.
14. Kan Z., Jaiswal B.S., Stinson J., Janakiraman V., Bhatt D., Stern H.M., Yue P., Haverty P.M., Bourgon R., Zheng J., et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010, 466:869-873.
15. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., Gazdar A., Powell S.M., Riggins G.J., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304:554.
16. Sjoblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., Mandelker D., Leary R.J., Ptak J., Silliman N., et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314:268-274.
17. Stephens P., Edkins S., Davies H., Greenman C., Cox C., Hunter C., Bignell G., Teague J., Smith R., Stevens C., et al. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet 2005, 37:590-592.
18. Wood L.D., Calhoun E.S., Silliman N., Ptak J., Szabo S., Powell S.M., Riggins G.J., Wang T.L., Yan H., Gazdar A., et al. Somatic mutations of GUCY2F, EPHA3, and NTRK3 in human cancers. Hum Mutat 2006, 27:1060-1061.
19. Delfino F.J., Stevenson H., Smithgall T.E. A growth-suppressive function for the c-fes protein-tyrosine kinase in colorectal cancer. J Biol Chem 2006, 281:8829-8835.
20. Luo J., Emanuele M.J., Li D., Creighton C.J., Schlabach M.R., Westbrook T.F., Wong K.K., Elledge S.J. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009, 137:835-848.
21. Scholl C., Frohling S., Dunn I.F., Schinzel A.C., Barbie D.A., Kim S.Y., Silver S.J., Tamayo P., Wadlow R.C., Ramaswamy S., et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009, 137:821-834.
22. Iorns E., Turner N.C., Elliott R., Syed N., Garrone O., Gasco M., Tutt A.N., Crook T., Lord C.J., Ashworth A. Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 2008, 13:91-104.
23. Carter H., Samayoa J., Hruban R.H., Karchin R. Prioritization of driver mutations in pancreatic cancer using cancer-specific high-throughput annotation of somatic mutations (CHASM). Cancer Biol Ther 2010, 10:582-587.
24. McDermott U., Sharma S.V., Dowell L., Greninger P., Montagut C., Lamb J., Archibald H., Raudales R., Tam A., Lee D., et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A 2007, 104:19936-19941.
25. MacKeigan J.P., Murphy L.O., Blenis J. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat Cell Biol 2005, 7:591-600.
26. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., Miliaresis C., Rodgers L., McCombie R., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275:1943-1947.
27. Maehama T., Dixon J.E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998, 273:13375-13378.
28. Samuels Y., Diaz L.A., Schmidt-Kittler O., Cummins J.M., Delong L., Cheong I., Rago C., Huso D.L., Lengauer C., Kinzler K.W., et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005, 7:561-573.
29. Carpten J.D., Faber A.L., Horn C., Donoho G.P., Briggs S.L., Robbins C.M., Hostetter G., Boguslawski S., Moses T.Y., Savage S., et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007, 448:439-444.
30. Poliseno L., Salmena L., Zhang J., Carver B., Haveman W.J., Pandolfi P.P. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 2010, 465:1033-1038.
31. López-Knowles E., O'Toole S.A., McNeil C.M., Millar E.K., Qiu M.R., Crea P., Daly R.J., Musgrove E.A., Sutherland R.L. PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer 2010, 126:1121-1131.
32. Calleja V., Alcor D., Laguerre M., Park J., Vojnovic B., Hemmings B.A., Downward J., Parker P.J., Larijani B. Intramolecular and intermolecular interactions of protein kinase B define its activation in vivo. PLoS Biol 2007, 5:e95.
33. Guertin D.A., Stevens D.M., Thoreen C.C., Burds A.A., Kalaany N.Y., Moffat J., Brown M., Fitzgerald K.J., Sabatini D.M. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell 2006, 11:859-871.
34. Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101.
35. Peterson T.R., Laplante M., Thoreen C.C., Sancak Y., Kang S.A., Kuehl W.M., Gray N.S., Sabatini D.M. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009, 137:873-886.
36. Brognard J., Newton A.C. PHLiPPing the switch on Akt and protein kinase C signaling. Trends Endocrinol Metab 2008, 19:223-230.
37. Brognard J., Niederst M., Reyes G., Warfel N., Newton A.C. Common polymorphism in the phosphatase PHLPP2 results in reduced regulation of Akt and protein kinase C. J Biol Chem 2009, 284:15215-15223.
38. Hirano I., Nakamura S., Yokota D., Ono T., Shigeno K., Fujisawa S., Shinjo K., Ohnishi K. Depletion of Pleckstrin homology domain leucine-rich repeat protein phosphatases 1 and 2 by Bcr-Abl promotes chronic myelogenous leukemia cell proliferation through continuous phosphorylation of Akt isoforms. J Biol Chem 2009, 284:22155-22165.
39. Liu J., Weiss H.L., Rychahou P., Jackson L.N., Evers B.M., Gao T. Loss of PHLPP expression in colon cancer: role in proliferation and tumorigenesis. Oncogene 2009, 28:994-1004.
40. Pei H., Li L., Fridley B.L., Jenkins G.D., Kalari K.R., Lingle W., Petersen G., Lou Z., Wang L. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell 2009, 16:259-266.
41. Brognard J., Sierecki E., Gao T., Newton A.C. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell 2007, 25:917-931.
42. Gao T., Furnari F., Newton A.C. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 2005, 18:13-24.
43. Yang W.L., Wang J., Chan C.H., Lee S.W., Campos A.D., Lamothe B., Hur L., Grabiner B.C., Lin X., Darnay B.G., et al. The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science 2009, 325:1134-1138.
44. Harrington L.S., Findlay G.M., Gray A., Tolkacheva T., Wigfield S., Rebholz H., Barnett J., Leslie N.R., Cheng S., Shepherd P.R., et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 2004, 166:213-223.
45. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., Lane H., Hofmann F., Hicklin D.J., Ludwig D.L., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006, 66:1500-1508.
46. Um S.H., Frigerio F., Watanabe M., Picard F., Joaquin M., Sticker M., Fumagalli S., Allegrini P.R., Kozma S.C., Auwerx J., et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 2004, 431:200-205.
47. Sarbassov D.D., Ali S.M., Sengupta S., Sheen J.H., Hsu P.P., Bagley A.F., Markhard A.L., Sabatini D.M. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006, 22:159-168.
48. Wan X., Harkavy B., Shen N., Grohar P., Helman L.J. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007, 26:1932-1940.
49. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
50. Wan P.T., Garnett M.J., Roe S.M., Lee S., Niculescu-Duvaz D., Good V.M., Jones C.M., Marshall C.J., Springer C.J., Barford D., et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116:855-867.
51. Sebolt-Leopold J.S. Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway. Clin Cancer Res 2008, 14:3651-3656.
52. Hatzivassiliou G., Song K., Yen I., Brandhuber B.J., Anderson D.J., Alvarado R., Ludlam M.J., Stokoe D., Gloor S.L., Vigers G., et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010, 464:431-435.
53. Heidorn S.J., Milagre C., Whittaker S., Nourry A., Niculescu-Duvas I., Dhomen N., Hussain J., Reis-Filho J.S., Springer C.J., Pritchard C., et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010, 140:209-221.
54. Poulikakos P.I., Zhang C., Bollag G., Shokat K.M., Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010, 464:427-430.
55. Hirai H., Maru Y., Hagiwara K., Nishida J., Takaku F. A novel putative tyrosine kinase receptor encoded by the eph gene. Science 1987, 238:1717-1720.
56. Pasquale E.B. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 2010, 10:165-180.
57. Genander M., Halford M.M., Xu N.J., Eriksson M., Yu Z., Qiu Z., Martling A., Greicius G., Thakar S., Catchpole T., et al. Dissociation of EphB2 signaling pathways mediating progenitor cell proliferation and tumor suppression. Cell 2009, 139:679-692.
58. Prevostel C., Alvaro V., Vallentin A., Martin A., Jaken S., Joubert D. Selective loss of substrate recognition induced by the tumour-associated D294G point mutation in protein kinase Calpha. Biochem J 1998, 334(Pt 2):393-397.
59. Vallentin A., Lo T.C., Joubert D. A single point mutation in the V3 region affects protein kinase Calpha targeting and accumulation at cell-cell contacts. Mol Cell Biol 2001, 21:3351-3363.
60. Zhu Y., Dong Q., Tan B.J., Lim W.G., Zhou S., Duan W. The PKCalpha-D294G mutant found in pituitary and thyroid tumors fails to transduce extracellular signals. Cancer Res 2005, 65:4520-4524.
61. Lopez-Bergami P., Habelhah H., Bhoumik A., Zhang W., Wang L.H., Ronai Z. RACK1 mediates activation of JNK by protein kinase C [corrected]. Mol Cell 2005, 19:309-320.
62. Leroy C., Fialin C., Sirvent A., Simon V., Urbach S., Poncet J., Robert B., Jouin P., Roche S. Quantitative phosphoproteomics reveals a cluster of tyrosine kinases that mediates SRC invasive activity in advanced colon carcinoma cells. Cancer Res 2009, 69:2279-2286.
63. Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J., Lee K., Reeves C., Li Y., et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007, 131:1190-1203.
64. Shackelford D.B., Shaw R.J. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 2009, 9:563-575.
65. Zagorska A., Deak M., Campbell D.G., Banerjee S., Hirano M., Aizawa S., Prescott A.R., Alessi D.R. New roles for the LKB1-NUAK pathway in controlling myosin phosphatase complexes and cell adhesion. Sci Signal 2010, 3:ra25.
66. Sanz-Moreno V., Gadea G., Ahn J., Paterson H., Marra P., Pinner S., Sahai E., Marshall C.J. Rac activation and inactivation control plasticity of tumor cell movement. Cell 2008, 135:510-523.
67. Fukata Y., Kimura K., Oshiro N., Saya H., Matsuura Y., Kaibuchi K. Association of the myosin-binding subunit of myosin phosphatase and moesin: dual regulation of moesin phosphorylation by Rho-associated kinase and myosin phosphatase. J Cell Biol 1998, 141:409-418.
68. Yamashiro S., Yamakita Y., Totsukawa G., Goto H., Kaibuchi K., Ito M., Hartshorne D.J., Matsumura F. Myosin phosphatase-targeting subunit 1 regulates mitosis by antagonizing polo-like kinase 1. Dev Cell 2008, 14:787-797.
69. Lochhead P.A., Wickman G., Mezna M., Olson M.F. Activating ROCK1 somatic mutations in human cancer. Oncogene 2010, 29:2591-2598.
70. Hallberg B., Palmer R.H. Crizotinib-latest champion in the cancer wars?. N Engl J Med 2010, 363:1760-1762.
71. Ferrer-Costa C., Gelpi J.L., Zamakola L., Parraga I., de la Cruz X., Orozco M. PMUT: a web-based tool for the annotation of pathological mutations on proteins. Bioinformatics 2005, 21:3176-3178.
72. Kaminker J.S., Zhang Y., Watanabe C., Zhang Z. CanPredict: a computational tool for predicting cancer-associated missense mutations. Nucleic Acids Res 2007, 35:W595-598.
73. Kaminker J.S., Zhang Y., Waugh A., Haverty P.M., Peters B., Sebisanovic D., Stinson J., Forrest W.F., Bazan J.F., Seshagiri S., et al. Distinguishing cancer-associated missense mutations from common polymorphisms. Cancer Res 2007, 67:465-473.
74. Lahiry P., Torkamani A., Schork N.J., Hegele RA Kinase mutations in human disease: interpreting genotype-phenotype relationships. Nat Rev Genet 2010, 11:60-74.